摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-5-fluoro-2,6-dimethylpyrimidine | 1240622-52-9

中文名称
——
中文别名
——
英文名称
4-chloro-5-fluoro-2,6-dimethylpyrimidine
英文别名
——
4-chloro-5-fluoro-2,6-dimethylpyrimidine化学式
CAS
1240622-52-9
化学式
C6H6ClFN2
mdl
MFCD16988366
分子量
160.578
InChiKey
FHODBPHCANOZIG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    203.6±35.0 °C(Predicted)
  • 密度:
    1.288±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of 3-Azabicyclo[3.2.0]heptane-Derived Building Blocks via [3+2] Cycloaddition
    作者:Anton A. Homon、Oleksandr V. Hryshchuk、Serhii Trofymchuk、Oleg Michurin、Yuliya Kuchkovska、Dmytro S. Radchenko、Oleksandr O. Grygorenko
    DOI:10.1002/ejoc.201800972
    日期:2018.11.1
    Synthesis of 3‐azabicyclo[3.2.0]heptane‐derived building blocks via [3+2]cycloaddition of cyclobutene‐1‐carboxylate and azomethine ylide is described. It is shown that the title bicyclic scaffold is a three‐dimensional template which is well‐compatible with lead‐oriented parallel synthesis.
    描述了通过环丁烯-1-羧酸酯和甲亚胺叶立德的[3 + 2]环加成反应合成3-氮杂双环[3.2.0]庚烷的结构单元。结果表明标题双环支架是一个三维模板,与基于的平行合成很好地兼容。
  • [EN] HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUESEN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2X7
    申请人:AXXAM SPA
    公开号:WO2022129365A1
    公开(公告)日:2022-06-23
    The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    本发明涉及一种具有P2X7受体(P2X7)拮抗作用的新型1,4-取代哌啶化合物(I)的制备方法,以及包含这些化合物的药物组合物,化学过程和它们在治疗或预防与P2X7受体活性相关的动物疾病,特别是人类疾病中的应用。
  • HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
    申请人:AXXAM S.p.A.
    公开号:EP4015039A1
    公开(公告)日:2022-06-22
    The present invention relates to novel 1,4-substituted piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans
    本发明涉及具有 P2X7 受体(P2X7)拮抗特性的新型式(I)1,4-取代哌啶化合物、包含这些化合物的药物组合物、制备这些化合物的化学工艺及其在治疗或预防动物(尤其是人类)体内与 P2X7 受体活性有关的疾病中的用途。
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    申请人:ViiV HEALTHCARE UK (NO.5) LIMITED
    公开号:US20200360384A1
    公开(公告)日:2020-11-19
    Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
  • BAX INHIBITORS AND USES THEREOF
    申请人:CASE WESTERN RESERVE UNIVERSITY
    公开号:US20220389028A1
    公开(公告)日:2022-12-08
    A compound having formula (I) or (II) for use inhibiting Bax mediated cell death and/or apoptosis.
查看更多